Netherlands· NL-eecd63d6706c
Mestinon 10, tabletten 10 mg
A pyridostigmine product containing pyridostigminebromide, registered in Netherlands by Viatris Healthcare B.V.. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Pyridostigmine is registered in 16 of 19 countries.
Countries holding a registration under ATC N07AA02 (pyridostigmine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Pyridostigmine · ATC N07AA02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pyridostigmine costs, country by country.
Normalised to the WHO defined daily dose (0.18 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pyridostigmine · price per daily dose (0.18 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.06
- FR France$1.63
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- PYRIDOSTIGMINEBROMIDE
- Manufacturer
- Viatris Healthcare B.V.
- Country
- Netherlands (NL)
- ATC code
- N07AA02
- ATC class
- Pyridostigmine
- Defined daily dose
- 0.18 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id03820
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
106 interactions on record for pyridostigmine.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pyridostigmine · interactions on record
106 records
- 2 severe
- 56 moderate
- 48 info
Most severe, free to view
- SiponimodL04AA42severe
- SiponimodL04AE03severe
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pyridostigmine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenMestinon 10 mg Tablett2care4 ApS
- NorwayMestinonOrifarm AS
- SwitzerlandMestinon, TablettenMEDA Pharmaceuticals Switzerland GmbH
- FinlandMestinonViatris Oy
- United KingdomPyridostigmine bromide 10mg tabletsSpecial Order
- United StatesMestinonBausch Health US, LLC
- GermanyAmindanDesitin Arzneimittel Gmbh
- CzechiaMESTINONMylan IRE Healthcare Limited, Dublin
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Mestinon
- Belgium · Mestinon
- Bulgaria · Калимин
- Czechia · Mestinon
- Germany · Amindan, Kalymin
- Denmark · Mestinon, Pyridostigminbromid Orifarm
- Estonia · Kalymin, Mestinon
- Spain · Mestinon
- Finland · Mestinon
- France · Mestinon, Mestinon Lp
- United Kingdom (Northern Ireland) · Mestinon, Pyridostigmine Bromide
- Greece · Mestinon
- Croatia · Mestinon 60
- Hungary · Mestinon
- Ireland · Mestinon
- Italy · Mestinon
- Luxembourg · Mestinon
- Latvia · Kalymin 60 N, Mestinon
- Malta · Mestinon
- Norway · Mestinon
- Poland · Mestinon, Stygmistanon
- Portugal · Mestinon
- Romania · Mestinon
- Sweden · Mestinon, Pyridostigmin Orifarm
- Slovenia · Mestinon
- Slovakia · Mestinon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/22a821cb-da70-4737-a8a8-26eb9683bc39 GET /v1/drugs/22a821cb-da70-4737-a8a8-26eb9683bc39?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h03820_smpc.pdf",
"strength": null,
"atc_label": "Pyridostigmine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg03820",
"excipients": [
"AARDAPPELZETMEEL, GEPREGELATINEERD",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"MAÏSZETMEEL",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)"
],
"substances": [
"PYRIDOSTIGMINEBROMIDE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h03820.pdf",
"authorised_at": "1990/05/20",
"procedure_number": null,
"dispensing_status": "Uitsluitend recept",
"registration_number": "03820",
"additional_monitoring": "N"
}See everything about pyridostigmine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.